BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, October 6, 2024
See today's BioWorld
Home
» Deals and M&As remain level through April; more than a third for COVID-19
To read the full article
sign up for free
or
sign in
.
Deals and M&As remain level through April; more than a third for COVID-19
May 22, 2020
By
Karen Carey
No Comments
Of the 160 biopharma deals tracked by
BioWorld
during the month of April, 36% are for collaborations focusing on the development of therapeutics and vaccines for COVID-19.
BioWorld
Analysis and data insight
Coronavirus